Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

Summary

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment Participants will: * Visit the clinic three times every 28 days for treatment and tests * Have CT or MRI scans every 8 weeks while on treatment

Timeline

Start

2030-01

Primary completion

2035-01

Completion

2040-01

Drugs

Indications